Integrated Cancer Repository for Cancer Research
Purpose
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.
Conditions
- Pancreatic Cancer
- Thyroid Cancer
- Lung Cancer
- Esophageal Cancer
- Thymus Cancer
- Colon Cancer
- Rectal Cancer
- Gastrointestinal Stromal Tumors
- Anal Cancer
- Bile Duct Cancer
- Duodenal Cancer
- Gallbladder Cancer
- Gastric Cancer
- Liver Cancer
- Small Intestine Cancer
- Peritoneal Surface Malignancies
- Familial Adenomatous Polyposis
- Lynch Syndrome
- Bladder Cancer
- Kidney Cancer
- Penile Cancer
- Prostate Cancer
- Testicular Cancer
- Ureter Cancer
- Urethral Cancer
- Hypopharyngeal Cancer
- Laryngeal Cancer
- Lip Cancer
- Oral Cavity Cancer
- Nasopharyngeal Cancer
- Oropharyngeal Cancer
- Paranasal Sinus Cancer
- Nasal Cavity Cancer
- Salivary Gland Cancer
- Skin Cancer
- Central Nervous System Tumor
- Central Nervous System Cancer
- Mesothelioma
- Breast Cancer
- Leukemia
- Melanoma
- Sarcoma
- Unknown Primary Tumor
- Multiple Myeloma
- Ovarian Cancer
- Endometrial Cancer
- Vaginal Cancer
- Neuroendocrine Tumors
- Plasma Cell Dyscrasia
- Healthy Control
Eligibility
- Eligible Ages
- Between 19 Years and 110 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
. - Adult individuals (male and female) who have a personal diagnosis/history of cancer - Adult individuals who have a risk for developing cancer or suspicious clinical findings - Adult individuals with no history of cancer for normal control registry. - Able to provide consent. - 19 years of age or older. - Adult individuals who are able to speak English or Spanish.
Exclusion Criteria
. - Individuals under age 19. - Individuals unable to provide informed consent by virtue of cognitive impairment. - Anyone who does not meet the above inclusion criteria for this project. - Non-English or Non-Spanish speaking individuals.
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Recruiting Locations
Greenwood Village, Colorado 80111
Daytona Beach, Florida 32117
DeLand, Florida 32720
Orange City, Florida 32763
Palm Coast, Florida 32164
Tallahassee, Florida 32308
Aurora, Illinois 60504
Yorkville, Illinois 60560
Fort Wayne, Indiana 46845
Indianapolis, Indiana 46219
Indianapolis, Indiana 46227
Council Bluffs, Iowa 51503
Michael Zlomke, MD
712-396-4117
Waterloo, Iowa 50702
Overland Park, Kansas 66213
Randallstown, Maryland 21133
Westminster, Maryland 21157
Holyoke, Massachusetts 01040
Aitkin, Minnesota 56431
Brainerd, Minnesota 56401
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Fergus Falls, Minnesota 56537
Kansas City, Missouri 64086
Kansas City, Missouri 64111
Kansas City, Missouri 64118
Liberty, Missouri 64068
Saint Joseph, Missouri 64507
Bozeman, Montana 59715
Kalispell, Montana 59901
Hastings, Nebraska 68901
Norfolk, Nebraska 68701
North Platte, Nebraska 69101
Omaha, Nebraska 68114
Russell Smith, MD
Omaha, Nebraska 68114
Omaha, Nebraska 68198
Glens Falls, New York 12801
Fayetteville, North Carolina 28304
Kenneth Manning, MD
Fargo, North Dakota 58103
Minot, North Dakota 58701
Alliance, Ohio 44601
Rutland, Vermont 05701
Green Bay, Wisconsin 54305
More Details
- NCT ID
- NCT02012699
- Status
- Recruiting
- Sponsor
- University of Nebraska
Detailed Description
The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2project.org) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred & Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically-interoperable and easily-customizable cancer data resource which is aimed at collecting, managing, mining and sharing the comprehensive, multi-dimensional cancer-related data on cancer patients and biospecimens (such as tumor specimens, germ line DNA, serum, urine, and plasma) collected from those individuals. The iCaRe2 provides: (i) a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; (ii) utilization of standard vocabulary and data elements; and (iii) the ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care. The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries: (i) the Pancreatic Cancer Collaborative Registry (PCCR) established in 2001, (ii) the Breast Cancer Collaborative Registry (BCCR) established in 2006, (iii) the Thyroid Cancer Collaborative Registry (TCCR) established in 2006, and (iv) the Great Plains Health Informatics Database (GPHID) established in 2011, to enroll subjects who have no personal history of cancer diagnosis at the time of enrollment. At present, this framework has been incrementally expanded to include the Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal & Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), Non-Melanoma Skin Cancer Registry (NMSC) and Auxiliary Cancer Registry (ACR). The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. It was felt that these latter models implied that the registry or network would assume control of an individual Center's database. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. It was also recognized that for this model to be successful, it is essential to have a standardized approach to data collection (patient information and biospecimen annotation) and reporting. A confederation would also encourage participation of any interested Center, irrespective of its size or location. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data.